The lines were obtained from individuals who presented with the classic features of RMC with both patients being young (<45 years old), having sickle cell trait, and presenting with metastatic disease disseminating from RMC tumors that demonstrated loss of SMARCB1 (SNF5/INI‐1) staining.1, 2, 3, 4, 5, 6, 8, 9, 10 The loss of SMARCB1 (SNF5/INI‐1) in the UOK353 cell line correlated with a translocation between chromosomes 19 and 22 consistent with a recent study describing balanced translocations involving the SMARCB1 locus on chromosome 22.9 This evidence concerns the gene SMARCB1 and metastatic neoplasm.